Dario Pasquale Anobile

Dario Pasquale Anobile

Auto-generated profile, based on publicly available information

Dario Pasquale Anobile

Department of Oncology University of Torino, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DADario P. Anobile
Dario P. Anobile
Iris Chiara SalaroglioIris Chiara Salaroglio
Iris Chiara Salaroglio
FTFabrizio Tabbo'
Fabrizio Tabbo'
SVSofia La Vecchia
Sofia La Vecchia
MAMuhlis Akman
Muhlis Akman
Chiara RigantiChiara Riganti
Chiara Riganti
Purpose: The response to immune checkpoint inhibitors (ICI) often differs between genders in non–small cell lung cancer (NSCLC), but metanalyses results are controversial, and no clear mechanisms are defined. We aim at clarifying the molecular circuitries explaining the differential gender-related response to anti–PD-1/anti–PD-L1 agents in NSCLC. Experimental Design: We prospectively analyzed a cohort of patients with NSCLC treated with ICI as a first-line approach, and we identified the molecular mechanisms determining the differential efficacy of ICI in 29 NSCLC cell lines of both genders, recapitulating patients’ phenotype. We validated new immunotherapy strategies in mice bearing NSCLC patient-derived xenografts and human reconstituted immune system (“immune-PDXs”). Results: In patients, we found that estrogen receptor α (ERα) was a predictive factor of response to pembrolizumab, stronger than gender and PD-L1 levels, and was directly correlated with PD-L1 expression, particularly in female patients. ERα transcriptionally upregulated CD274/PD-L1 gene, more in females than in males. This axis was activated by 17-β-estradiol, autocrinely produced by intratumor aromatase, and by the EGFR-downstream effectors Akt and ERK1/2 that activated ERα. The efficacy of pembrolizumab in immune-PDXs was significantly improved by the aromatase inhibitor letrozole, which reduced PD-L1 and increased the percentage of antitumor CD8+T-lymphocytes, NK cells, and Vγ9Vδ2 T-lymphocytes, producing durable control and even tumor regression after continuous administration, with maximal benefit in 17-β-estradiol/ERα highfemale immune-xenografts. Conclusions: Our work unveils that 17-β-estradiol/ERα status predicts the response to pembrolizumab in patients with NSCLC. Second, we propose aromatase inhibitors as new gender-tailored immune-adjuvants in NSCLC. See related commentary by Valencia et al., p. 3832

6 September 2024 in Cancer Letters
Verified
Journal Article
Open access
SVSofia La Vecchia
Sofia La Vecchia
SFSimona Fontana
Simona Fontana
ISIris Chiara Salaroglio
Iris Chiara Salaroglio
DADario Pasquale Anobile
Dario Pasquale Anobile
SDSabrina Digiovanni
Sabrina Digiovanni
Chiara RigantiChiara Riganti
Chiara Riganti
Immune checkpoints inhibitors (ICIs) as anti-PD-1/anti-PD-L1 have been approved as first-line treatment in patients with non-small cell lung cancer (NSCLC), but only 25 % of patients achieve durable response. We previously unveiled that estrogen receptor α transcriptionally up-regulates PD-L1 and aromatase inhibitors such as letrozole increase the efficacy of pembrolizumab. Here we investigated if letrozole may have additional immune-sensitizing mechanisms. We found that higher the level of PD-L1 in NSCLC, higher the activation of SREBP1c that transcriptionally increases fatty acid synthase and stearoyl-CoA desaturase enzymes, increasing the amount of polyunsaturated fatty acids (PUFAs). Letrozole further up-regulated SREBP1c-mediated transcription of lipogenic genes, and increased the amount of PUFAs, thereby leading to greater membrane fluidity and reduced binding between PD-L1 and PD-1. The same effects were observed upon supplementation with ω3-PUFA docosahexaenoic acid (DHA) that enhanced the efficacy of pembrolizumab in humanized NSCLC immune-xenografts. We suggest that PUFA enrichment in membrane phospholipids improves the efficacy of ICIs. We propose to repurpose letrozole or DHA as new immune-sensitizing agents in NSCLC.

25 November 2025
Verified
Other
Open access
DADario P. Anobile
Dario P. Anobile
Iris Chiara SalaroglioIris Chiara Salaroglio
Iris Chiara Salaroglio
FTFabrizio Tabbo'
Fabrizio Tabbo'
SVSofia La Vecchia
Sofia La Vecchia
MAMuhlis Akman
Muhlis Akman
Chiara RigantiChiara Riganti
Chiara Riganti
Levels of progesterone, testosterone and respective receptors in non-small cell lung cancer cells a-b. Levels of progesterone (panel a) and testosterone (panel b), measured by ELISA (technical triplicates), in female (F)-derived NCI-H1385 and NCI-H1975 cells, and in male (M)-derived A549 and NCI-H1650 cells. Data are means+SD (n=3, biological replicates). °p<0.05: M-derived cells versus mean of F-derived cells (ANOVA). c-d. Progesterone receptor (PR; panel c) and androgen receptor (AR; panel d) mRNA, measured by RT-PCR (technical triplicates). The relative expression of each gene in NCI-H1385 cells was considered 1. Data are means + SD (n=3, biological replicates). ***p<0.001: NCI-H1975 cells versus NCI-H1385; °°p<0.01: M-derived cells versus mean of F-derived cells (ANOVA). e. Immunoblot of the indicated proteins in nuclear extracts. TBP is included as control of equal protein loading. The image is representative of one of three experiments.

25 November 2025
Verified
Other
Open access
DADario P. Anobile
Dario P. Anobile
Iris Chiara SalaroglioIris Chiara Salaroglio
Iris Chiara Salaroglio
FTFabrizio Tabbo'
Fabrizio Tabbo'
SVSofia La Vecchia
Sofia La Vecchia
MAMuhlis Akman
Muhlis Akman
Chiara RigantiChiara Riganti
Chiara Riganti
Disaggregated data of PD-L1 and ERα in non-small cell lung cancer patients, according to ages, tumor stages and smoking habits. Expression of PD-L1 (panel a) and ERα (panel b) mRNA, measured by RT-PCR (technical triplicates) in tumor samples of 35 NSCLC patients, according to pathological classification (T: primary tumors; N: lymph nodes involved; M: metastasis), clinical stages (III-IV stage), smoking habits (never smoker: NSm; former smoker: FSm; current smoker: CSm). *p<0.05, **p<0.01, ***p<0.001: T versus N+M, III vs IV, NSM+FSm vs CSm (ANOVA).

25 November 2025
Verified
Other
Open access
DADario P. Anobile
Dario P. Anobile
Iris Chiara SalaroglioIris Chiara Salaroglio
Iris Chiara Salaroglio
FTFabrizio Tabbo'
Fabrizio Tabbo'
SVSofia La Vecchia
Sofia La Vecchia
MAMuhlis Akman
Muhlis Akman
Chiara RigantiChiara Riganti
Chiara Riganti
Molecular circuitries linking ERα and PD-L1. ERα, activated by the binding of 17-β-estradiol and by the phosphorylation on Ser118 via the EGFR/Akt and EGFR/ERK1/2 axes, upregulates PD-L1 and predicts a better response to pembrolizumab. However, lowering the synthesis of 17-β-estradiol with letrozole or the activity of ERα with fulvestrant sensitizes non-small cell lung cancer to pembrolizumab, relieving the PD-L1-dependent immune-suppression, allowing the expansion and activity of anti-tumor infiltrating lymphocytes, such as CD8+T-cells, NK cells and Vγ9Vδ2+T cells. We suggest the existence of four possible scenarios, depending on sex, EGFR activity, 17-β-estradiol/ERα and PD-L1 status, with a differential sensitivity to pembrolizumab and aromatase inhibitors:1) male patients with low 17-β-estradiol synthesis, low EGFR signaling, low ERα amount/activity and low PD-L1 amount; 2) male patients with high EGFR signaling, high ERα amount/activity but low 17-β-estradiol synthesis, with intermediate PD-L1 amount; 3) female patients with low EGFR signaling, low ERα amount/activity but high 17-β-estradiol synthesis, with intermediate PD-L1 amount; 4) female patients with high EGFR signaling, high ERα amount/activity, high 17-β-estradiol synthesis and high PD-L1 amount. The efficacy of pembrolizumab and the additional benefit of aromatase inhibitors increased progressively from scenario 1 to 4.